DNX-2401の新興薬剤に関する洞察と市場予測：2032年

DNAtrixが開発したDNX-2401は、高い効力と安全性という2つの要件を満たすように設計された腫瘍溶解免疫療法です。これを達成するために、アデノウイルスのゲノムに2つの安定した遺伝子変化を導入し、網膜芽細胞腫（Rb）経路欠損細胞で選択的に複製し、腫瘍細胞に効率的に感染するようにしました。前臨床試験および臨床試験の結果は、DNX-2401がヒト腫瘍内で複製され、腫瘍壊死を誘発し、腫瘍内免疫細胞浸潤を誘発し、長期的な腫瘍破壊につながることを示しています。

DNX-2401は、がん細胞内で選択的に複製され、腫瘍破壊を引き起こし、さらに隣接する腫瘍細胞に腫瘍溶解性ウイルスを拡散させることにより、腫瘍細胞殺傷の連鎖反応を引き起こすことによって作用します。このプロセスが腫瘍に対する免疫反応を引き起こします。DNAtrixは、rGBM患者を対象にペムブロリズマブとの併用療法を検討する第III相試験（IGNITE）を計画しています。

今後数年間で、多形性膠芽腫（GBM）の市場シナリオは、世界中の広範な研究と医療支出の増加により変化します。各社は、病状を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、DNX-2401の優位性に影響を与える可能性のある機会を模索しています。GBMを対象とした他の新興製品がDNX-2401と厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるDNX-2401市場について調査し、市場の概要とともに、2026年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 多形性膠芽腫（GBM）に対するDNX-2401の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 DNX-2401市場評価

• GBMに対するDNX-2401の市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国におけるGBMに対するDNX-2401の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: DNX-2401, Clinical Trial Description, 2023
• Table 2: DNX-2401, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: DNX-2401 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: DNX-2401 Market Size in the US, in USD million (2019-2032)
• Table 7: DNX-2401 Market Size in Germany, in USD million (2019-2032)
• Table 8: DNX-2401 Market Size in France, in USD million (2019-2032)
• Table 9: DNX-2401 Market Size in Italy, in USD million (2019-2032)
• Table 10: DNX-2401 Market Size in Spain, in USD million (2019-2032)
• Table 11: DNX-2401 Market Size in the UK, in USD million (2019-2032)
• Table 12: DNX-2401 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: DNX-2401 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: DNX-2401 Market Size in the United States, USD million (2019-2032)
• Figure 3: DNX-2401 Market Size in Germany, USD million (2019-2032)
• Figure 4: DNX-2401 Market Size in France, USD million (2019-2032)
• Figure 5: DNX-2401 Market Size in Italy, USD million (2019-2032)
• Figure 6: DNX-2401 Market Size in Spain, USD million (2019-2032)
• Figure 7: DNX-2401 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: DNX-2401 Market Size in Japan, USD million (2019-2032)

“"DNX-2401 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about DNX-2401 for glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the DNX-2401 for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the DNX-2401 for GBM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DNX-2401 market forecast analysis for GBM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in GBM.

Drug Summary:

DNX-2401, explored by DNAtrix, is an oncolytic immunotherapy designed to fulfill the dual requirements of high potency and safety. To achieve this, two stable genetic changes in the adenovirus genome were engineered that cause it to replicate selectively in retinoblastoma (Rb) pathway deficient cells and infect tumor cells efficiently. Results from preclinical and clinical studies indicate that DNX-2401 replicates in human tumors, elicits tumor necrosis, triggers intra tumoral immune cell infiltration, and can lead to long-term tumor destruction.

It works by setting off a chain reaction of tumor cell killing by selectively replicating within cancer cells, causing tumor destruction and further spreading the oncolytic virus to adjacent tumor cells. This process then triggers an immune response directed against the tumor. DNAtrix is planning a Phase III study (IGNITE) to investigate the drug as a combination with pembrolizumab for rGBM patients.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the DNX-2401 description, mechanism of action, dosage and administration, research and development activities in glioblastoma multiforme (GBM).
• Elaborated details on DNX-2401 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the DNX-2401 research and development activities in GBM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around DNX-2401.
• The report contains forecasted sales of DNX-2401 for GBM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for GBM.
• The report also features the SWOT analysis with analyst views for DNX-2401 in GBM.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DNX-2401 Analytical Perspective by DelveInsight

In-depth DNX-2401 Market Assessment

This report provides a detailed market assessment of DNX-2401 for glioblastoma multiforme (GBM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

DNX-2401 Clinical Assessment

The report provides the clinical trials information of DNX-2401 for GBM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for glioblastoma multiforme (GBM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DNX-2401 dominance.
• Other emerging products for GBM are expected to give tough market competition to DNX-2401 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DNX-2401 in GBM.
• Our in-depth analysis of the forecasted sales data of DNX-2401 from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DNX-2401 in GBM.

Key Questions:

• What is the product type, route of administration and mechanism of action of DNX-2401?
• What is the clinical trial status of the study related to DNX-2401 in glioblastoma multiforme (GBM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DNX-2401 development?
• What are the key designations that have been granted to DNX-2401 for GBM?
• What is the forecasted market scenario of DNX-2401 for GBM?
• What are the forecasted sales of DNX-2401 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to DNX-2401 for GBM?
• Which are the late-stage emerging therapies under development for the treatment of GBM?

Table of Contents

1. Report Introduction

2. DNX-2401 Overview in GBM

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. DNX-2401 Market Assessment

• 5.1. Market Outlook of DNX-2401 in GBM
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of DNX-2401 in the 7MM for GBM
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of DNX-2401 in the United States for GBM
  • 5.3.2. Market Size of DNX-2401 in Germany for GBM
  • 5.3.3. Market Size of DNX-2401 in France for GBM
  • 5.3.4. Market Size of DNX-2401 in Italy for GBM
  • 5.3.5. Market Size of DNX-2401 in Spain for GBM
  • 5.3.6. Market Size of DNX-2401 in the United Kingdom for GBM
  • 5.3.7. Market Size of DNX-2401 in Japan for GBM

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options